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The aim of present study was the assessment of antimicrobial activity of prepared time-dependent 
release bilayer tablets of amoxicillin trihydrate and in vitro evaluation of drug release by antimicrobial 
assay using agar plate diffusion method. The bilayer tablets comprised of a delayed and sustained 
release layer. Direct compression method was used for the preparation of bilayer tablets containing 
Eudragit-L100 D55 as delayed release polymer, and HPMCK4M and HPMCK15 as sustained release 
polymers. The prepared bilayer tablets containing amoxicillin trihydrate were evaluated for hardness, 
thickness, friability, weight variation and drug content. Further, in vitro drug release was assessed by 
antimicrobial assay using S. aureus and E. coli as test microorganisms. The aliquot samples of in vitro 
drug release study were found to be effective against both microorganisms for 16 hours due to sustained 
action. The in vitro drug release study and antimicrobial assay showed that bilayer tablets have sustained 
release profile of drug delivery with time-dependent burst release after a lag-time of 2 hours. The lower 
MIC value (2 µg/mL) of prepared bilayer tablets vis-à-vis marketed preparation (5 µg/mL) represented 
its good antimicrobial activity.
Uniterms: Chronotherapeutics. Time-dependent release. In vitro dissolution. Minimum inhibitory 
concentration. Zone of inhibition.
O objetivo do presente estudo foi avaliar a atividade antimicrobiana de formulações de comprimidos 
de dupla camada contendo amoxicilina triidratada para liberação tempo dependente e avaliação da 
liberação in vitro do fármaco pelo ensaio de atividade antimicrobiana utilizando o método de difusão 
em placa de ágar. Os comprimidos de dupla camada consistem em uma camada para liberação retardada 
e outra sustentada. O método de compressão direta foi usado para a preparação dos comprimidos de 
dupla camada contendo Eudragit-L 100 D55 como polímero para liberação retardada e HPMCK4M ou 
HPMCK15 como polímeros para liberação sustentada. As formulações de comprimidos de dupla camada 
contendo amoxicilina triidratada foram avaliadas quanto a dureza, espessura, friabilidade, variação de 
peso e conteúdo de fármaco. Além disso, a liberação do fármaco in vitro foi avaliada por ensaio de 
atividade antimicrobiana usando S. aureus e E. coli como microrganismos teste. A alíquota das amostras 
do estudo de liberação do fármaco in vitro demonstrou ser efetiva contra ambos os microrganismos por 
um período de 16 horas devido à ação sustentada. O estudo de liberação do fármaco in vitro e o ensaio 
de atividade antimicrobiana mostraram que os comprimidos de dupla camada tiveram um perfil de 
liberação sustentada do fármaco com um pico de liberação após 2 horas de ensaio. O menor valor de 
MIC (2 ug/mL) dos comprimidos de dupla camada quando comparados à formulação comercial (5 ug/
mL) representa uma boa atividade antimicrobiana.
Unitermos: Cromoterapia. Liberação tempo-dependente. Dissolução in vitro. Concentração inibitória 
mínima. Zona de inibição.
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INTRODUCTION
Time-dependent release systems are designed to 
deliver drugs after a particular lag-time period. Lag-time 
equates to the time taken for the drug to release from 
a dosage form at the absorption site (Aurora, Talwar, 
Pathak, 2006; Singh et al. 2010). Over the past few years, 
pharmaceutical formulators and scientists have shown 
increasing interest in the development of time-dependent 
release systems for controlled release delivery of drugs 
(Akhgari, Sadeghi, Garekani, 2006, 2009).
Bacterial infections are the chronobiological dis-
eases whose progression depends upon the circadian 
rhythm of the body. Growth cycle of bacteria involves 
four different phases such as lag phase, exponential phase, 
stationary phase and decline phase. The bacterial growth is 
higher during reproductive phase specifically in the early 
daytime, which is a chronobiology-mediated phenomenon. 
The time-dependent release systems of antibiotics are 
useful as they provide drug release from the dosage form 
by mimicking the bacterial reproduction cycle to achieve 
higher Cmax, AUC and to reduce the bacterial population 
(Cha, Rybak, 2004; Sun, Lee, Banevicius, Du, Maglio, 
Nicolau, 2005; Leuthner, Cheung, Rybak, 2006).
Amoxicillin trihydrate (AMT), chemically α-amino 
hydroxyl benzyl penicillin, is a broad spectrum semi-syn-
thetic penicillin belonging to the β-lactam family (Hervey, 
1991). It has been found to be highly effective against 
gram-positive and gram-negative bacteria especially for 
Helicobacter pylori by inhibiting their cell wall synthesis 
(Donowitz, Mandell, 1988; Sahasathian et al., 2007). It 
binds to penicillin-binding proteins of the inner membrane 
of the bacterial cell wall. In actively growing cells, the 
binding of amoxicillin within the cell wall leads to inter-
ference with production of peptidoglycan, and subsequent 
lysis of the cell in an iso-osmotic environment (Papich, 
1987; Yellanki, Singh, Ali, 2010). AMT is susceptible 
to degradation by β-lactamase producing bacteria. Fur-
ther, low plasma protein binding (20%) and very low t1/2 
(1-1.5 hours) and lack of stability in gastric acidic pH 
calls for the design of novel pharmaceutical formulations 
(Wilson, Lee, Mukherji, 2002). Several formulation ap-
proaches have been explored to develop sustained release 
dosage forms of AMT to address the above-mentioned 
problems (Bonev, Hopper, Parisot, 2008; Hilton, Deasy, 
1992; Patel, Amiji, 1996; Risbud, Hardikar, Bhat, 2000). 
The novel time-dependent release bilayer tablets com-
prised of a delayed release layer (i.e., Eudragit-L100 D55 
as pH dependent enteric polymer which releases the drug 
after specific lag-time), and a sustained release layer (i.e., 
HPMCK4M and HPMCK15). Thus, the prime objectives 
behind designing the once-a-day bilayer tablet formulation 
of AMT were to provide gastric protection, lower the mini-
mum inhibitory concentration (MIC) and subsequently 
improve the patient compliance.
The present studies, therefore, entails the method of 
preparation of time-dependent release bilayer tablets of 
amoxicillin trihydrate and evaluation of its antimicrobial 
activity using agar plate diffusion method.
MATERIAL AND METHODS
Material
AMT was generous gift sample from M/s Ranbaxy 
Laboratories Ltd., Gurgaon, India. Eudragit-L100 D55, 
HPMCK4M, and HPMCK15 were purchased from M/s 
Colorcon Asia Ltd., (Mumbai, India). Aerosil-200, silicified 
microcrystalline cellulose (Prosolv-HD60) and magnesium 
stearate were obtained from M/s FMC Biopolymer (Mum-
bai, India). All other reagents and chemicals used were of 
analytical grade. Deionized double-distilled water (Milipore 
Corporation, USA) was used throughout the study.
Method of preparation of bilayer tablets
The time-dependent release bilayer tablets containing 
divided dose of amoxicillin trihydrate in delayed release 
layer and sustained release layer were prepared by direct 
compression method. The total dose of AMT in the matrix 
tablet was kept as 900 mg, which was equivalent to 775 mg 
of amoxicillin, i.e., once-daily dose for AMT in treatment 
of bacterial infections. The delayed release layer contained 
145 mg of AMT and sustained release layer contained 
755 mg of AMT. The delayed release granules were pre-
pared by wet granulation method. Drug was granulated with 
Eudragit-L100 D55 dissolved in acetone. The wet mass 
was passed through sieve no. 18 (#BSS), and dried in hot 
air oven at 40 oC for 20 min. Finally magnesium stearate 
was mixed with dried granules for lubrication. Similarly, 
sustained release granules were prepared by dry blending 
of drug with excipients. Finally both the layers were com-
pressed into a single bilayer tablet by direct compression 
technique using (20 x 9 mm) capsule-shaped punch in a 
rotary tablet compression machine (Cadmach India Ltd., In-
dia). The compositions of prepared time-dependent release 
bilayer tablets of AMT are shown in Table I.
Characterization
Evaluation of delayed release granules
The prepared delayed release granules were evalu-
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TABLE I - Composition of time-dependent bilayer tablet of amoxicillin trihydrate
Composition (Delayed release layer) F1 F2 F3 F4 F5 F6
Amoxicillin 145 145 145 145 145 145
Eudragit-L100 D55 23 33 43 53 63 73
MCC-PH101 80 70 60 50 40 30
Mg. Stearate 2 2 2 2 2 2
Total 250 250 250 250 250 250
Composition (Sustained release layer) F1 F2 F3 F4 F5 F6
Amoxicillin 755 755 755 755 755 755
HPMCK4 50 60 70 _ _ _
HPMCK15 _ _ _ 50 60 70
Prosolv-HD60 91 81 71 91 81 71
Aerosil 6 6 6 6 6 6
Mg. Stearate 8 8 8 8 8 8
Total 900 900 900 900 900 900
*All the quantities expressed are in mg
ated for micromeritic properties like percentage loss on 
drying (%LOD), angle of repose, bulk density and tapped 
density, Carr’s compressibility index and Hausner’s ratio.
Evaluation of bilayer tablets
The different formulations of time-dependent release 
bilayer tablets were evaluated for hardness, thickness, fri-
ability, weight variation and drug content as per USPXXI 
specifications. For drug content evaluation, 20 tablets were 
weighed and crushed into powder. An accurately weighed 
quantity of powder was suitably dissolved in phosphate 
buffer (pH 7.4), appropriate dilutions were made and 
analysed by UV-Visible spectrophotometer to calculate 
the percentage drug content. The acceptance criteria of 
all these tests were based on the USPXXI specifications.
In vitro drug release
In vitro drug release from the prepared bilayer tablets 
was performed using USP Type-1 dissolution apparatus 
using SGF (pH 1.2) (900 mL) for first 2 hours followed by 
phosphate buffer (pH 7.4) (900 mL) for upto 16 hours at 
50 rpm/37±0.5 0C. Aliquot samples (5 mL) were taken at 
various time intervals (0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 
and 16 hours), replaced with fresh media, filtered through 
0.45 µm nylon filter (Millipore, Mumbai, India) and absor-
bance was determined spectrophotometrically at 273 nm. 
Further, the %drug release was determined and a plot was 
constructed between time (h) versus cumulative %drug 
release. Similarly, dissolution study was performed for 
marketed preparation Amoxil® (Dabur, India), containing 
AMT equivalent to 500 mg, using USP Type-I apparatus 
with phosphate buffer (pH 7.4, 900 mL, 50 rpm/37±0.5 oC) 
for 4 hours. At specific time intervals (0.5, 0.75, 1, 1.5, 2, 
2.5, 3, 3.5 and 4 hours) aliquots (5 mL) were collected, 
filtered and analysed spectrophotometrically. The in 
vitro drug release samples were further subjected to anti-
microbial activity evaluation using specific test organisms.
Assay of AMT and antibacterial activity assessment
The tablet formulations which showed optimum drug 
release were taken for further evaluation using antimi crobial 
activity. The antimicrobial assay of bilayer tablets of AMT 
was performed using agar plate diffusion method. The 
different dilutions of standard were prepared in distilled 
water with concentrations ranging from 1-250 µg/mL. The 
aliquots obtained after dissolution were filtered through 
0.45 µm nylon filter (Millipore, Mumbai, India). Each 
1 mL of the filtered samples was carefully transferred into 
the wells prepared with sterile borer on solidified nutrient 
agar (Himedia, India) plate in petridishes inoculated with 
test gram positive cocci, S. aureus (ATCC29213), and gram 
negative bacilli, E. coli (ATCC25922). After inoculation, 
petri-dishes were kept in an incubator (Remi Corporation, 
India) at 37 oC for 24 hours. After incubation the zone of 
inhibition (ZOI) for time-dependent release bilayer tablet, 
marketed preparation and standard dilution of antibiotic 
were measured with the help of slide calliper scale in mm. 
The concentration of AMT in aliquot samples was calcu-
lated using the following equation (1): 
 . (1)
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Where, MIC is the minimum inhibitory concentra-
tion, x is the zone of inhibition (mm), c is the concentration 
of antibiotic (µg/mL), D is the diffusion coefficient, and 
t is the time required for antibiotic diffusion. A plot was 
made between x2 vs. ln (c) graphs for standard dilutions of 
the antibiotic using each test organism. From this graph, 
the unknown concentration of AMT present in samples ob-
tained after dissolution of bilayer tablets can be determined 
by extrapolating zone of inhibition (x) with respect to the 
concentration (c) for each microbial strain to find out the 
%drug release. This helps in establishing the correlation 
between the in vitro drug release and anti-microbial assay.
RESULTS
Evaluation of delayed release granules
The micromeritic properties of the granules are 
given in the Table II. The %LOD was found to be less 
than 13%, while other parameters like angle of repose 
(25-30%), Carr’s index (12-16%) and Hausner’s ratio 
(<1.25) for all the formulations are within the acceptable 
range, indicated good flow property and compressibility.
Evaluation of bilayer tablets
The prepared bilayer tablets were capsular in shape 
with good physical appearance. Thickness, hardness, 
friability, weight variation and drug content of all formu-
lations were found to be satisfactory as shown in Table 
III. Results indicated that all batches of prepared tablet 
formulations met the USPXXI specifications with thick-
ness <5%, hardness 18 kg/cm2, friability <1% and weight 
variation ±10%. Drug content uniformity was within 
98.9±0.35 to 102.4±0.16%, respectively.
In vitro drug release and antibacterial activity 
assessment
The in vitro drug release profile of different batches 
of time-dependent release bilayer tablet formulations are 
depicted in Figure 1. The formulation F2 showed optimum 
time-dependent release with more than 85% drug release 
in 16 h. This optimized formulation was subjected to an-
timicrobial activity evaluation using agar plate diffusion 
method as discussed above. According to equation (1), x2 
vs. ln (c) plots were drawn using zone of inhibition data 
of control against S. aureus and E. coli as obtained from 
agar plate diffusion assay in Figure 2 and Figure 3. The 
correlation coefficient values for these plots were found 
to be 0.9983 and 0.9876 indicated good linearity. From 
these plots, the concentration of AMT from in vitro drug 
release samples of bilayer tablets was determined by com-
paring their zones of inhibition (mm) data with respective 
concentrations (µg/mL) for each test organism (Table IV).
The in vitro drug release profile of time-dependent 
release bilayer tablets using S. aureus and E. coli as test 
organisms is shown in Figure 4. Further, the in vitro drug 
release profile using S. aureus and E. coli were compared 
by plotting y-axis and x-axis, respectively. The R2 value 
was found to be 0.9939 (Figure 5), showing a positive 
correlation between the assay results of two different 
TABLE II - Micromeritic properties of delayed release granules of AMT
Formulation code % LOD (Loss on drying)
Angle of repose 
(θ)
Bulk density 
(g/mL)
Tapped density 
(g/mL)
Carr’s Index 
(%)
Hausner’s 
Ratio
F1
F2
F3
F4
F5
F6
13.0
12.9
13.1
13.0
12.9
13.2
26.9
28.2
29.9
28.6
26.4
27.1
1.14
1.14
1.13
1.14
1.14
1.13
1.32
1.30
1.31
1.31
1.32
1.33
13.6
12.3
15.9
12.9
13.6
15.0
1.15
1.14
1.15
1.14
1.15
1.17
TABLE III - Technological characterization of sustained release tablets of AMT (Mean± S.D, n=6)
Formulation code Thickness (mm) Hardness (kg/cm2) Friability (%) Weight variation (mg) Drug content (%)
F1
F2
F3
F4
F5
F6
7.2±0.02
7.1±0.04
7.3±0.07
7.0±0.00
7.2±0.06
7.4±0.08
18.4±0.06
18.2±0.04
18.9±0.03
18.4±0.06
18.2±0.08
18.3±0.09
0.90
0.61
0.54
0.55
0.65
0.52
1151±0.06
1149±0.08
1152±0.03
1151±0.07
1152±0.12
1150±0.01
100±0.04
98.91±0.14
100.5±0.07
101.9±0.06
101±0.06
98.91±0.35
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TABLE IV - Antibacterial activity of control samples against S. 
aureus ATCC29213 and E. coli ATCC25922
Concentration 
(µg/mL)
ZOI in (mm ± S.D.) 
S. aureus ATCC29213
ZOI in (mm ± S.D.) 
E. coli ATCC25922
0 0 0
1 0 0
2 19.6±2.5 19.0±1.6
5 23.3±1.5 23.0±2.0
10 29.3±2.1 30.3±1.5
15 34.3±1.5 35.0±2.4
20 41.6±1.5 39.7±1.5
50 48.3±2.5 44.7±2.5
100 50.0±1.0 46.7±1.8
200 51.3±1.5 51.3±1.1
250 58.2±1.8 56.2±2.3
ZOI- Zone of inhibition; n=6
FIGURE 1 - In vitro drug release profile of time-dependent 
release bilayer tablet containing AMT by dissolution study.
FIGURE 2 - x2 vs. ln (c) plot of control (standard amoxicillin 
trihydrate) using S. aureus. x = zone of inhibition (mm); c = 
concentration of control samples (µg/mL)
FIGURE 3 - x2 vs. ln (c) plot of control (standard amoxicillin 
trihydrate) using E. coli. x = zone of inhibition (mm); c = 
concentration of control samples (µg/mL)
organisms and also indicated that AMT estimation from 
the drug release samples was not affected by bacterial 
strains used in this investigation. Figure 6 and Figure 7 
depicts the zone of inhibition of standard dilutions of AMT 
against S. aureus and E. coli. It was observed that zones of 
inhibition for these two different bacteria were almost the 
same. In vitro drug release data showed that AMT release 
from time-dependent release bilayer tablet was sustained 
up to 16 hours and delayed release occurred after 2 hours. 
Figure 8 and Figure 9 depicts the zone of inhibition of 
samples obtained from in vitro drug release study of time-
dependent release tablet of amoxicillin trihydrate against 
S. aureus and E. coli.
Table IV, V represented the zone of inhibition 
of time-dependent release bilayer tablet and marketed 
preparation (Amoxil®) of AMT performed using agar 
FIGURE 4 - Comparative in vitro drug release profiles of 
optimized time-dependent release bilayer tablet containing AMT 
using S. aureus and E. coli as test organisms.
plate diffusion employing S. aureus and E. coli. Table V 
represents the zone of inhibitions of standard dilutions of 
the AMT. The observations showed that zone of inhibition 
of bilayer tablets after dissolution upto 0.5 h matches with 
zone of inhibition of standard dilutions of pure antibiotic at 
2 µg/mL, whereas zone of inhibition of marketed prepara-
tion matches with zone of inhibition of standard dilutions 
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of pure drug at 5 µg/mL concentration. This indicated that 
bilayer tablets have lower value of MIC as compared to 
marketed preparation in the test organisms used.
The optimized time-dependent release bilayer 
tablet formulation showed maximum zone of inhibition 
of 76.1±2.05 mm in gram-positive and 74.0±1.07 mm in 
gram-negative bacteria within 16 hours, while marketed 
immediate release tablets showed maximum zone of in-
hibition of 49.4±2.00 mm in gram-positive and 49.9±1.05 
in gram-negative bacteria within 4 hours. Further, a 
prominent increase in zone of inhibition was observed with 
dissolution after 2 hours in time-dependent release formu-
lation due to burst release of antibiotic to kill the viable 
growth of microorganisms and showed good correlation 
with in vitro drug release data. This indicated the higher ef-
ficacy of time-dependent release bilayer tablet formulation 
FIGURE 5 - Comparative in vitro drug release profiles of 
optimized time-dependent release bilayer tablet containing AMT 
using S. aureus and E. coli as test organisms.
TABLE V - Antibacterial activity indicating the ZOI of samples 
obtained from in vitro drug release study of time-dependent 
bilayer release matrix tablet of amoxicillin trihydrate against S. 
aureus ATCC29213 and E. coli ATCC25922
Dissolution 
time (h)
ZOI in (mm ± S.D.) 
S. aureus ATCC29213
ZOI in (mm ± S.D.) 
E. coli ATCC25922
0 0 0
0.5 27.2±3.06 25.1±2.08
1 30.3±1.53 28.4±3.51
2 32.3±1.53 32.3±3.06
3 44.0±1.00 40.1±3.93
4 46.7±1.53 44.7±2.21
5 51.7±2.08 50.0±2.92
6 57.7±1.53 57.4±1.53
7 60.2±3.06 59.7±2.01
8 61.4±2.00 60.9±1.05
10 62.5±1.13 61.5±1.17
12 66.7±1.46 64.7±1.28
16 69.1±1.33 67.8±1.77
ZOI- Zone of inhibition; n=6
FIGURE 9 - The pictures depicting zone of inhibition of samples 
obtained from in vitro drug release study of time-dependent 
release bilayer tablet formulation (F2) of AMT in E. coli.
FIGURE 8 - The pictures depicting zone of inhibition of samples 
obtained from in vitro drug release study of time-dependent 
release bilayer tablet formulation (F2) of AMT in S. aureus.
FIGURE 7 - The pictures depicting zone of inhibition of different 
standard dilutions of (1-250 µg/mL) against E. coli.
FIGURE 6 - The pictures depicting zone of inhibition of different 
standard dilutions of (1-250 µg/mL) against S. aureus.
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over conventional immediate release marketed preparation 
due to the low MIC and enhanced antimicrobial action.
CONCLUSION
The time-dependent release bilayer tablets of AMT 
were prepared and evaluated for its antibacterial activity. 
The in vitro drug release from these tablets was estimated 
by antimicrobial assay using agar plate diffusion method. 
The aliquot dissolution samples of bilayer tablet formu-
lation were found to be sensitive against both the test 
organisms, S. aureus and E. coli over 24 hours study. The 
drug release from bilayer tablet was found to be sustained 
up to 16 hours with burst release achieved after 2 hours. 
Furthermore, the MIC of prepared time-dependent release 
bilayer tablets was found to be 2 µg/mL, while marketed 
conventional tablet preparation was found to be 5 µg/mL. 
The lower MIC indicated higher anti-microbial activity 
of the prepared bilayer tablet formulation to arrest the 
growth of microorganisms. Thus, chronotherapeutics 
by time-dependent release bilayer tablets containing 
amoxicillin trihydrate may be more effective alternative 
over conventional dosage forms for the management of 
bacterial infections.
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